<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01167738</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000681691</org_study_id>
    <secondary_id>PACT-17</secondary_id>
    <secondary_id>2010-020979-23</secondary_id>
    <nct_id>NCT01167738</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy With or Without Metformin Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer</brief_title>
  <acronym>PACT-17</acronym>
  <official_title>A Randomized Phase II Study of Chemotherapy Â± Metformin in Metastatic Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS San Raffaele</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRCCS San Raffaele</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor&#xD;
      cells, either by killing the cells or by stopping them from dividing. Giving more than one&#xD;
      drug (combination chemotherapy) may kill more tumor cells. Metformin hydrochloride may stop&#xD;
      the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not&#xD;
      yet known if combination chemotherapy is more effective with or without metformin&#xD;
      hydrochloride in treating patients with metastatic pancreatic cancer.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying giving cisplatin, epirubicin&#xD;
      hydrochloride, capecitabine, and gemcitabine hydrochloride together with metformin&#xD;
      hydrochloride to see how well it works compared to cisplatin, epirubicin hydrochloride,&#xD;
      capecitabine, and gemcitabine hydrochloride alone in treating patients with metastatic&#xD;
      pancreatic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To assess the therapeutic activity of chemotherapy comprising cisplatin, epirubicin&#xD;
           hydrochloride, capecitabine, and gemcitabine hydrochloride with versus without metformin&#xD;
           hydrochloride in terms of 6-month progression-free survival in patients with metastatic&#xD;
           pancreatic cancer.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To assess the overall survival of patients treated with this regimen.&#xD;
&#xD;
        -  To assess the response rate in patients treated with this regimen.&#xD;
&#xD;
        -  To assess the duration of response in patients treated with this regimen.&#xD;
&#xD;
        -  To assess the toxicity in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive cisplatin, epirubicin hydrochloride, and gemcitabine&#xD;
           hydrochloride on days 1 and 15. Patients will also receive capecitabine and metformin&#xD;
           hydrochloride on days 1-28. Treatment repeats every 4 weeks for up to 6 courses in the&#xD;
           absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
        -  Arm II: Patients receive cisplatin, epirubicin hydrochloride, gemcitabine hydrochloride,&#xD;
           and capecitabine as in arm I. Treatment repeats every 4 weeks for up to 6 courses in the&#xD;
           absence of disease progression or unacceptable toxicity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    concern of detrimental effect&#xD;
  </why_stopped>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival at 6 months</measure>
    <time_frame>every 2 months</time_frame>
    <description>CT scan</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>every 14 days during therapy; every 3 months thereafter</time_frame>
    <description>outpatient visit, phone interview</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>every 2 months</time_frame>
    <description>CT scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>every 2 weeks</time_frame>
    <description>outpatient visit, laboratory findings</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>PEXG regimen + metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>cisplatin and epirubicin at 30 mg/mq on days 1 and 15, capecitabine at 1250 mg/mq days 1-28, gemcitabine at 800 mg/mq on days 1 and 15, Metformin at 2 g days 1-28</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PEXG regimen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>cisplatin and epirubicin at 30 mg/mQ on days 1 and 15, capecitabine at 1250 mg/mq days 1-28, gemcitabine at 800 mg/mq on days 1 and 15</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
    <description>1250 mg/mq days 1-28 every 4 weeks</description>
    <arm_group_label>PEXG regimen</arm_group_label>
    <arm_group_label>PEXG regimen + metformin</arm_group_label>
    <other_name>XELODA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>30 mg/mq on days 1 and 15 every 4 weeks</description>
    <arm_group_label>PEXG regimen</arm_group_label>
    <arm_group_label>PEXG regimen + metformin</arm_group_label>
    <other_name>cisplatino TEVA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epirubicin</intervention_name>
    <description>30 mg/mq on days 1 and 15 every 4 weeks</description>
    <arm_group_label>PEXG regimen</arm_group_label>
    <arm_group_label>PEXG regimen + metformin</arm_group_label>
    <other_name>farmorubicina</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine</intervention_name>
    <description>800 mg/mq on days 1 and 15 every 4 weeks</description>
    <arm_group_label>PEXG regimen</arm_group_label>
    <arm_group_label>PEXG regimen + metformin</arm_group_label>
    <other_name>GEMZAR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metformin</intervention_name>
    <description>2 g days 1-28 every 4 weeks</description>
    <arm_group_label>PEXG regimen + metformin</arm_group_label>
    <other_name>glucophage</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed pancreatic adenocarcinoma&#xD;
&#xD;
               -  Metastatic (stage IV) disease&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  No symptomatic brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Karnofsky performance status 60-100%&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Adequate bone marrow, liver and kidney function&#xD;
&#xD;
          -  No previous or concurrent malignancies at other sites except for surgically cured&#xD;
             carcinoma in-situ of the cervix, basal cell or squamous cell carcinoma of the skin, or&#xD;
             other neoplasms without evidence of disease within the past 5 years&#xD;
&#xD;
          -  No multiple severe diseases which would compromise safety (i.e., cardiac failure,&#xD;
             previous myocardial infarction within the past 4 months, cardiac arrhythmia, or&#xD;
             history of psychiatric disabilities)&#xD;
&#xD;
          -  No alcohol abuse&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior chemotherapy or metformin&#xD;
&#xD;
          -  No other concurrent experimental drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michele Reni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Scientifico H. San Raffaele</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Istituto Scientifico H. San Raffaele</name>
      <address>
        <city>Milan</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <study_first_submitted>July 21, 2010</study_first_submitted>
  <study_first_submitted_qc>July 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2010</study_first_posted>
  <last_update_submitted>April 23, 2015</last_update_submitted>
  <last_update_submitted_qc>April 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS San Raffaele</investigator_affiliation>
    <investigator_full_name>Michele Reni</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>adenocarcinoma of the pancreas</keyword>
  <keyword>stage IV pancreatic cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

